The global vaccine adjuvants market size reached US$ 996.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,639.3 Million by 2032, exhibiting a growth rate (CAGR) of 11.1% during 2024-2032. More Info:- https://www.imarcgroup.com/vaccine-adjuvants-market

1. Global Vaccine
Adjuvants Market
Research and Forecast
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved

2. About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on management
strategy and market research worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their most critical challenges, and
transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods
are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.

3. Report Highlight
and Description
According to the latest report by IMARC Group, titled "Vaccine Adjuvants
Market: Global Industry Trends, Share, Size, Growth, Opportunity and
Forecast 2024-2032," the global vaccine adjuvants market size reached US$
996.5 Million in 2023.
Vaccine adjuvants, in the realm of immunology and healthcare, play a pivotal
role in enhancing the effectiveness of vaccines. These specialized substances
are formulated to augment the body’s immune response to a vaccine, ensuring
a more robust and lasting defense against diseases.
Vaccine adjuvants are designed to work in tandem with vaccines, making them
a critical component in the field of vaccination. They also serve as catalysts,
bolstering the body’s ability to recognize and combat pathogens, ultimately
leading to improved vaccine efficacy.
Request for a PDF sample of this report:
https://www.imarcgroup.com/vaccine -adjuvants-market/requestsample

4. Report Description
Global Vaccine Adjuvants Market Trends:
The market is driven by the increasing emphasis on preventive healthcare and the urgency to combat emerging
infectious diseases. In addition to this, a growing aging population worldwide is contributing to the rising demand
for vaccines. As older individuals often have weaker immune responses, the need for effective adjuvants to boost
vaccine potency becomes paramount. This demographic shift is fostering a favorable environment for vaccine
adjuvant manufacturers and developers. Furthermore, advancements in vaccine technology are fueling the
adoption of adjuvants.
Novel vaccine formulations, including subunit, conjugate, and mRNA vaccines, are becoming more prevalent.
Vaccine adjuvants are integral to these formulations, enhancing their effectiveness. This trend is particularly
relevant as vaccine research explores new horizons beyond traditional live attenuated and inactivated vaccines.
Moreover, regulatory support and approvals are playing a pivotal role in market growth. Regulatory agencies are
recognizing the importance of vaccine adjuvants in vaccine development and are streamlining approval processes.
This is fostering innovation and competition within the market, as companies strive to meet stringent regulatory
requirements.
Looking forward, the market is anticipated to reach US$ 2,639.3 Million by 2032, expanding at a CAGR of
11.1% during the forecast period (2024-2032).
View Report TOC, Figures and Tables: https://www.imarcgroup.com/vaccine-adjuvants-market

5. Report
Segmentation
Breakup by Product Type:
• Adjuvant Emulsions
• Pathogen Components
• Particulate Adjuvants
• Combination Adjuvants
• Others
Breakup by Route of Administration:
• Oral
• Intramuscular
• Intranasal
• Subcutaneous
• Intradermal
• Others
Breakup by Diseases:
• Cancer

6. Report
Segmentation
• Infectious Diseases
• Others
Breakup by Application:
• Research
• Commercial
Breakup by Region:
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7. Competitive
Landscape with
Key Players
• Adjuvatis
• Agenus Inc.
• Croda International Plc
• CSL Limited
• Dynavax Technologies
• InvivoGen
• Novavax Inc.
• OZ Biosciences
• Phibro Animal Health Corporation
• SEPPIC
• SPI Pharma

8. Key Questions
Answered in
the Report
What was the size of the global vaccine adjuvants market in 2023?
What is the expected growth rate of the global vaccine adjuvants
market during 2024-2032?
What are the key factors driving the global vaccine adjuvants
market?
What has been the impact of COVID-19 on the global vaccine
adjuvants market?
What is the breakup of the global vaccine adjuvants market based
on the product type?
What is the breakup of the global vaccine adjuvants market based
on route of administration?

9. Key Questions
Answered in
the Report
What is the breakup of the global vaccine adjuvants market based
on the diseases?
What is the breakup of the global vaccine adjuvants market based
on the application?
What are the key regions in the global vaccine adjuvants market?
Who are the key players/companies in the global vaccine adjuvants
market?

10. Table of
Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Vaccine Adjuvants Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Adjuvant Emulsions
6.1.1 Mark et Trends
6.1.2 Mark et Forecast
6.2 Pathogen Components
6.2.1 Mark et Trends
6.2.2 Mark et Forecast
6.3 Particulate Adjuvants
6.3.1 Mark et Trends
6.3.2 Mark et Forecast

11. Table of
Contents
6.4 Combination Adjuvants
6.4.1 Mark et Trends
6.4.2 Mark et Forecast
6.5 Others
6.5.1 Mark et Trends
6.5.2 Mark et Forecast
7 Market Breakup by Route of Administration
7.1 Oral
7.1.1 Mark et Trends
7.1.2 Mark et Forecast
7.2 Intramuscular
7.2.1 Mark et Trends
7.2.2 Mark et Forecast
7.3 Intranasal
7.3.1 Market Trends
7.3.2 Mark et Forecast
7.4 Subcutaneous
7.4.1 Mark et Trends
7.4.2 Mark et Forecast
7.5 Intradermal
7.5.1 Mark et Trends
7.5.2 Mark et Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Mark et Forecast
8 Market Breakup by Diseases
8.1 Cancer
8.1.1 Mark et Trends
8.1.2 Mark et Forecast
For more information, visit :
https://www.imarcgroup.com/vaccine -adjuvants-market/toc

12. Disclaimer
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the
name of International Market Analysis Research and Consulting (IMARC). No part of this
publication may be reproduced, repackaged, redistributed or resold in whole or in any part.
The publication may also not be used in any form or by and means graphic electronic or
mechanical, including photocopying, recording, taping or by information storage or retrieval,
or by any other form, without the express consent of International Market Analysis Research
and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and
opinion have been based on information and sources believed to be accurate and reliable at
the time of publishing. International Market Analysis Research and Consulting makes no
representation of warranty of any kind as to the accuracy or completeness of any Information
provided. IMARC accepts no liability whatsoever for any loss or damage resulting from
opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of
International Market Analysis Research and Consulting. All other trademarks used in this
publication are registered trademarks of their respective companies.

13. Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com